ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 39397104

Efficacy analysis of HAIC combined with lenvatinib plus PD1 inhibitor vs. first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma.

Lin Z and 7 others. Sci Rep, 2024. Cited by 9 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Efficacy analysis of HAIC combined with lenvatinib plus PD1 inhibitor vs. first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma. Papers, record 39397104. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39397104

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy analysis of HAIC combined with lenvatinib plus PD1 inhibitor vs. first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma.
PubMed
Journal
Sci Rep
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
1.09, provisional
iCite
Revised in PubMed
2024-10-27
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lin ZZhipeng
2Zou XXugong
3Hu XXiaolong
4Huang DDabei
5Chen YYuan
6Lin JJiawen
7Li XXiaoqun
8Zhang JJian

Source PubMed

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CholangiocarcinomaMajor topic
QuinolinesMajor topic
Phenylurea CompoundsMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Humans
Male
Female
Middle Aged
Aged
Bile Duct Neoplasms
Gemcitabine
Infusions, Intra-Arterial
Adult
Treatment Outcome
Immune Checkpoint Inhibitors
Programmed Cell Death 1 Receptor
Deoxycytidine
Cisplatin
Progression-Free Survival

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
16,346,495Clinical pharmacology of hepatic arterial chemotherapy.Semin Oncol1983https://conductscience.org/library/papers/6346495PubMed
219,097,774New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer2009https://conductscience.org/library/papers/19097774PubMed
331,670,750Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.JAMA Oncol2020https://conductscience.org/library/papers/31670750PubMed
433,811,765Mechanistic Rationales Guiding Combination Hepatocellular Carcinoma Therapies Involving Immune Checkpoint Inhibitors.Hepatology2021https://conductscience.org/library/papers/33811765PubMed
532,606,456Cholangiocarcinoma 2020: the next horizon in mechanisms and management.Nat Rev Gastroenterol Hepatol2020https://conductscience.org/library/papers/32606456PubMed
6151,583A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil.Cancer Res1978https://conductscience.org/library/papers/151583PubMed
727,820,684Phase II Study of Hepatic Arterial Infusion Chemotherapy with Oxaliplatin and 5-Fluorouracil for Advanced Perihilar Cholangiocarcinoma.Radiology2017https://conductscience.org/library/papers/27820684PubMed
832,203,698Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.Lancet Oncol2020https://conductscience.org/library/papers/32203698PubMed
931,954,493mRECIST for HCC: Performance and novel refinements.J Hepatol2020https://conductscience.org/library/papers/31954493PubMed
1036,928,584Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.Signal Transduct Target Ther2023https://conductscience.org/library/papers/36928584PubMed

1 to 10 of 22

See all 22 references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
42,935,538Case Report: From unresectable to resectable: successful conversion therapy with TACE, HAIC, envafolimab, and olaparib in advanced intrahepatic cholangiocarcinoma.Front Oncol2026https://conductscience.org/library/papers/42935538PubMed
42,137,650Hepatic Artery Infusion Chemotherapy for Cholangiocarcinoma in 2025.Liver Cancer2026https://conductscience.org/library/papers/42137650PubMed
42,052,809Hepatic Arterial Infusion Chemotherapy Plus Systemic Chemotherapy, Lenvatinib and PD-(L)1 Inhibitors Versus Systemic Chemotherapy Plus PD-(L)1 Inhibitors in Advanced Intrahepatic Cholangiocarcinoma.Technol Cancer Res Treat2026https://conductscience.org/library/papers/42052809PubMed
41,417,116
Efficacy and safety of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1/PD-L1 inhibitors versus systemic chemotherapy plus lenvatinib and PD-1/PD-L1 inhibitors in advanced unresectable cholangiocarcinoma: a retrospective cohort study.
Cancer Immunol Immunother2025https://conductscience.org/library/papers/41417116PubMed
40,740,768Hepatic arterial infusion chemotherapy versus systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a meta-analysis of survival outcomes.Front Immunol2025https://conductscience.org/library/papers/40740768PubMed
40,697,239Pathological complete response in advanced intrahepatic cholangiocarcinoma was achieved through tri-modal therapy: A case report and review of literature.World J Gastrointest Oncol2025https://conductscience.org/library/papers/40697239PubMed
39,996,882Advancements in Locoregional Therapies for Unresectable Intrahepatic Cholangiocarcinoma.Curr Oncol2025https://conductscience.org/library/papers/39996882PubMed
39,867,877Hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and molecular targeted therapies for advanced infiltrative hepatocellular carcinoma: a single-center experience.Front Immunol2024https://conductscience.org/library/papers/39867877PubMed

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
PDCD15,133PubTator's text mininghttps://conductscience.org/library/genes/5133

Source NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39397104

GET https://conductscience.org/api/papers/v1/39397104/references?page=2

API referenceFor AI assistants